NHS rolls out ‘Biological Missile’ drug for resistant ovarian cancer. The first new targeted treatment in over 20 years
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over… read more.




